These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 702279)

  • 1. Plasma propranolol levels in beagle dogs after administration of propranolol hemisuccinate ester.
    Garceau Y; Davis I; Hasegawa J
    J Pharm Sci; 1978 Oct; 67(10):1360-3. PubMed ID: 702279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol.
    Shameem M; Imai T; Otagiri M
    J Pharm Pharmacol; 1993 Apr; 45(4):246-52. PubMed ID: 8098362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective oral bioavailability of 0-isovaleryl propranolol as a potential prodrug of propranolol.
    Shameem M; Imai T; Otagiri M
    J Pharmacobiodyn; 1992 Sep; 15(9):535-40. PubMed ID: 1287187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of propranolol in the dog.
    Tse FL; Sanders TM; Reo JP
    Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):180-9. PubMed ID: 7224706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of food on the intravenous and oral dose kinetics of propranolol in the dog.
    Bai SA; Walle UK; Walle T
    J Pharmacokinet Biopharm; 1985 Jun; 13(3):229-41. PubMed ID: 4087163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.
    Shameem M; Imai T; Yoshigae Y; Sparreboom A; Otagiri M
    J Pharm Sci; 1994 Dec; 83(12):1754-7. PubMed ID: 7891307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for the involvement of a pulmonary first-pass effect via carboxylesterase in the disposition of a propranolol ester derivative after intravenous administration.
    Imai T; Yoshigae Y; Hosokawa M; Chiba K; Otagiri M
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1234-42. PubMed ID: 14534358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and bioavailability of etintidine in beagle dogs: effects of routes of administration, doses, dosage forms, and chronic dosing.
    Huang SM; Abrams LS; Marriott TB; Weintraub HS
    Biopharm Drug Dispos; 1988; 9(1):71-83. PubMed ID: 3342286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hollow fibers as an oral sustained-release delivery system using propranolol hydrochloride.
    Hussain MA; DiLuccio RC; Shefter E; Hurwitz AR
    Pharm Res; 1989 Dec; 6(12):1052-5. PubMed ID: 2622860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1980 Jan; 27(1):22-31. PubMed ID: 7351114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.
    Von Bahr C; Hermansson J; Tawara K
    Br J Clin Pharmacol; 1982 Jul; 14(1):79-82. PubMed ID: 7104170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma propranolol before, during, and after cardiopulmonary bypass.
    Plachetka JR; Salomon NW; Copeland JG
    Clin Pharmacol Ther; 1981 Dec; 30(6):745-51. PubMed ID: 7307425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained propranolol delivery and increased oral bioavailability in dogs given a propranolol Laurate salt.
    Aungst BJ; Hussain MA
    Pharm Res; 1992 Nov; 9(11):1507-9. PubMed ID: 1475241
    [No Abstract]   [Full Text] [Related]  

  • 15. Kinetics of methylprednisolone and its hemisuccinate ester.
    Derendorf H; Möllmann H; Rohdewald P; Rehder J; Schmidt EW
    Clin Pharmacol Ther; 1985 May; 37(5):502-7. PubMed ID: 3886255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of propranolol.
    Routledge PA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):73-90. PubMed ID: 378502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High capacity for pulmonary first-pass elimination of propranolol in rats.
    Iwamoto K; Watanabe J; Aoyama Y
    J Pharm Pharmacol; 1987 Dec; 39(12):1049-51. PubMed ID: 2894439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of individual differences in gastric emptying to variability in plasma propranolol concentrations.
    Castleden CM; George CF; Short MD
    Br J Clin Pharmacol; 1978 Feb; 5(2):121-2. PubMed ID: 619945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.